transplantation and immunosuppression · reviewed 2026-08-01
Cyclosporine and fungal fermentation: the same molecule, formulations that are not interchangeable
A fungus produces cyclosporine itself, but a fungal culture is not a medicine. Even two pharmaceutical cyclosporine capsule forms can differ enough in bioavailability that the label says they are not interchangeable.
Defined medicine
cyclosporine modified capsules
ciclosporin · cyclosporine A · modified microemulsion capsules
Where it came from
Cyclosporine is an eleven-amino-acid cyclic polypeptide produced as a fungal metabolite. The label names the producing fungus as Beauveria nivea; NCBI Taxonomy records that name as a heterotypic synonym of Tolypocladium inflatum. dailymed-cyclosporine-modified ncbi-taxonomy-tolypocladium
What it is trying to achieve
The cited modified capsules are labelled to prevent rejection in kidney, liver, and heart transplants and for selected severe rheumatoid arthritis and plaque psoriasis uses under specialist management. dailymed-cyclosporine-modified
How it acts
Cyclosporine preferentially suppresses T-lymphocyte responses and inhibits production and release of immune signalling molecules including interleukin-2, thereby reducing immune reactions such as allograft rejection. dailymed-cyclosporine-modified
Why people developed this form
Clinical development turned a potent fungal immunosuppressant into a monitored medicine for preventing organ rejection and treating selected immune-mediated disease. The modified formulation has greater bioavailability than non-modified capsules, and the two are not bioequivalent. dailymed-cyclosporine-modified
Present form and manufacture
The cited modified capsule forms a microemulsion in water. The label states that modified and non-modified cyclosporine capsules are not bioequivalent and cannot be interchanged without physician supervision. dailymed-cyclosporine-modified
Bioavailability
Modified capsules have greater bioavailability than the cited non-modified product. Exposure varies among people and with food, grapefruit, and interacting medicines; interpretation and comparison of measured blood concentrations also depend on the assay used. Blood concentrations and organ function require monitoring. dailymed-cyclosporine-modified
Its own risks
Cyclosporine can cause nephrotoxicity, hepatotoxicity, hypertension, infection, and lymphoma or other neoplasia. Too much exposure can cause toxicity, while too little can permit transplant rejection. dailymed-cyclosporine-modified
What nature offers
No link below is assumed to be equivalent. Each names the organism or tradition, exact preparation, measured exposure, human evidence, and replacement boundary separately.
Nature link · Same molecule occurs in nature
cyclosporine-producing fungal culture
Tolypocladium inflatum
Beauveria nivea (name used in the cited label) · cyclosporine fungal metabolite
- Exact material
- Tolypocladium inflatum—the current NCBI Taxonomy name for the fungus called Beauveria nivea in the label—and the cyclosporine it produces, kept separate from crude culture, purified active ingredient, modified microemulsion capsule, and non-modified capsule. dailymed-cyclosporine-modified ncbi-taxonomy-tolypocladium
- Relationship
- Same molecule occurs in nature. Chemical identity may match, but purity, amount, formulation, route, companion compounds, and evidence can still differ.
Lineage
The fungus produces the final cyclosporine molecule itself. This is exact-molecule natural provenance, followed by purification and formulation rather than conversion into a different active molecule. dailymed-cyclosporine-modified ncbi-taxonomy-tolypocladium
Human evidence
Source, not an intervention Evidence product match: not applicable
The fungal organism, crude culture, and unformulated purified cyclosporine are source materials, not the controlled intervention described in the prescribing information. Their clinical efficacy and safety are not established by the capsule label. dailymed-cyclosporine-modified
Bioavailability and preparation
The label shows that formulation changes exposure even when the active molecule remains cyclosporine. No capsule bioavailability value can be transferred to a fungus, culture broth, or unformulated metabolite. dailymed-cyclosporine-modified
Safety
Fungal origin does not soften cyclosporine's immunosuppression, kidney, liver, blood-pressure, interaction, infection, or malignancy risks. The source organism has no established treatment safety in this record. dailymed-cyclosporine-modified
Can it replace the medicine?
A fungus, culture material, or unformulated metabolite is not a clinical substitute for monitored pharmaceutical cyclosporine; even finished cyclosporine formulations are not automatically equivalent. dailymed-cyclosporine-modified
The honest comparison
The same natural molecule can sit inside materially different interventions. Here purification, microemulsion behaviour, food and drug interactions, exposure assays, and monitoring separate a source organism from a medicine and a modified capsule from a non-modified capsule. dailymed-cyclosporine-modified
Cyclosporine is natural in molecular origin and uncompromisingly pharmaceutical in safe use. Its own label demonstrates why identical active-molecule names do not erase formulation, exposure, and monitoring differences. dailymed-cyclosporine-modified
Sources for this card
- Cyclosporine capsules USP modified prescribing information DailyMed · regulatory label · read 2026-08-01
- Taxonomy browser: Tolypocladium inflatum NCBI Taxonomy · official database · read 2026-08-01
Same card as data: /api/remedies/cyclosporine-fungal-fermentation.json. Found a source or claim problem? Open a correction.